205 related articles for article (PubMed ID: 34861126)
21. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.
Diniz H; Frazão JM
Nefrologia; 2013 Nov; 33(6):835-44. PubMed ID: 24158124
[TBL] [Abstract][Full Text] [Related]
22. Relationship between Fibroblast Growth Factor 23 and Biochemical and Bone Histomorphometric Alterations in a Chronic Kidney Disease Rat Model Undergoing Parathyroidectomy.
Liao HW; Hung PH; Hsiao CY; Liou HH; Lin HS; Huang TH; Jou IM; Tsai KJ
PLoS One; 2015; 10(7):e0133278. PubMed ID: 26186634
[TBL] [Abstract][Full Text] [Related]
23. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
Stubbs J; Liu S; Quarles LD
Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
[TBL] [Abstract][Full Text] [Related]
24. The roles of the skeleton and phosphorus in the CKD mineral bone disorder.
Hruska KA; Mathew S
Adv Chronic Kidney Dis; 2011 Mar; 18(2):98-104. PubMed ID: 21406294
[TBL] [Abstract][Full Text] [Related]
25. FGF23 Actions in CKD-MBD and other Organs During CKD.
Sun T; Yu X
Curr Med Chem; 2023; 30(7):841-856. PubMed ID: 35761503
[TBL] [Abstract][Full Text] [Related]
26. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
27. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
[TBL] [Abstract][Full Text] [Related]
28. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
29. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
Finch JL; Tokumoto M; Nakamura H; Yao W; Shahnazari M; Lane N; Slatopolsky E
Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1315-22. PubMed ID: 20200094
[TBL] [Abstract][Full Text] [Related]
30. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients.
Fayed A; El Nokeety MM; Heikal AA; Abdulazim DO; Naguib MM; Sharaf El Din UAA;
Ren Fail; 2018 Nov; 40(1):226-230. PubMed ID: 29619868
[TBL] [Abstract][Full Text] [Related]
32. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption.
Phelps KR; Mason DL
Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023
[TBL] [Abstract][Full Text] [Related]
33. Intestinal Phosphorus Absorption in Chronic Kidney Disease.
Stremke ER; Hill Gallant KM
Nutrients; 2018 Sep; 10(10):. PubMed ID: 30249044
[TBL] [Abstract][Full Text] [Related]
34. Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
Liu Z; Su G; Guo X; Wu Y; Liu X; Zou C; Zhang L; Yang Q; Xu Y; Ma W
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010350. PubMed ID: 26376110
[TBL] [Abstract][Full Text] [Related]
35. Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?
Ferreira JC; Ferrari GO; Neves KR; Cavallari RT; Dominguez WV; Dos Reis LM; Graciolli FG; Oliveira EC; Liu S; Sabbagh Y; Jorgetti V; Schiavi S; Moysés RM
PLoS One; 2013; 8(11):e79721. PubMed ID: 24236156
[TBL] [Abstract][Full Text] [Related]
36. The intervention effect of zuogui pill on chronic kidney disease-mineral and bone disorder regulatory factor.
Ma X; He L
Biomed Pharmacother; 2018 Oct; 106():54-60. PubMed ID: 29957466
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.
Courbon G; Martinez-Calle M; David V
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):359-366. PubMed ID: 32452919
[TBL] [Abstract][Full Text] [Related]
38. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome].
Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009
[TBL] [Abstract][Full Text] [Related]
39. High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic rats.
Bisson SK; Ung RV; Picard S; Valade D; Agharazii M; Larivière R; Mac-Way F
J Bone Miner Metab; 2019 Mar; 37(2):212-223. PubMed ID: 29603070
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of Action and Clinical Attributes of Auryxia
Ganz T; Bino A; Salusky IB
Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
